Global Gastrointestinal Stromal Tumor Market Analysis 2025-2030: Growth Drivers, Challenges, And Opportunities

The Gastrointestinal Stromal Tumor Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

How Big Is the Gastrointestinal Stromal Tumor Market Size Expected to Be by 2034?
The market for gastrointestinal stromal tumors has seen robust growth in recent times. The market is projected to escalate from $1.28 billion in 2024 to $1.37 billion in 2025, recording a compound annual growth rate (CAGR) of 7.2%. Factors contributing to the growth during the historic period include heightened awareness and early detection, the rise of targeted treatments, advancements in surgical methods, the genesis of individualized medicine, and progress in supportive care.

In the coming years, the market size for gastrointestinal stromal tumors is predicted to witness considerable growth, expected to reach $1.82 billion by 2029 with a compound annual growth rate (CAGR) of 7.4%. Factors such as ongoing research and drug development, an increase in patient-centered healTH*Care, precision medicine's prevalence in clinical practice, greater access to targeted therapies, and the enhancement of genomic profiling capabilities can be credited for the growth during the predicted period. The forecast period also sees emerging trends such as increased collaboration in R&D, advances in diagnostic technology, joint research and clinical trials, a heightened emphasis on early detection and diagnosis, and the investigation of combination therapies.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13248

What Are the Emerging Segments Within the Gastrointestinal Stromal Tumor Market?
The gastrointestinal stromal tumor market covered in this report is segmented -

1) By Treatment Type: Chemotherapy, Targeted Therapy, Other Treatment Types
2) By Indication: Stomach, Small Intestine, Others Indications
3) By End-User: Hospitals, Clinics, Specialized Cancer Treatment Centers, Other End-Users

Subsegments:
1) By Chemotherapy: Traditional Chemotherapy Agents, Combination Chemotherapy Regimens
2) By Targeted Therapy: Tyrosine Kinase Inhibitors, Other Targeted Agents
3) By Other Treatment Types: Surgery, Radiation Therapy, Clinical Trials For Novel Therapies

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13248&type=smp

What Long-Term Drivers Are Shaping Gastrointestinal Stromal Tumor Market Trends?
The upward trend in stomach cancer incidence is poised to spur the surge of the gastrointestinal stromal tumor market. This specific cancer type is characterized by an unchecked growth and multiplication of harmful cells in the stomach lining. Although gastrointestinal stromal tumors (GISTs) may appear within the stomach, they are not the same as stomach cancer. There's a heightened risk of developing additional cancers such as small bowel adenocarcinoma in GIST patients if two separate tumors converge and form a single tumor. It was projected by the American Cancer Society in January 2024 that approximately 26,890 new stomach cancer cases with 10,880 resultant deaths are expected in the U.S. for 2024. This constitutes 1.5% of all new cancer diagnoses. Hence, the escalating occurrence of stomach cancer is fueling the expansion of the gastrointestinal stromal tumor market. Concerning another driver of the gastrointestinal stromal tumor market, there's a mounting requirement for precision medicine poised to escalate the market growth. This method tailors medical treatment, decisions, therapies, and actions to fit the unique genetics and lifestyle of each patient. Precision medicine specific to gastrointestinal stromal tumors involves molecular profiling to detect certain mutations and hence, guides target therapies like imatinib. This increases the effectiveness of the treatment and reduces side effects through specifically designed interventions. Evidently, in February 2023, a report by the Personalized Medicine Coalition (PMC), disclosed that personalized medicines were responsible for 35% of novel approved NMEs in 2021. Even with 12 fresh approvals in 2022, they've maintained a steady share of no less than a quarter of new drug approvals over the prior eight years. Notably, this is a significant leap from the less than 10% recorded over ten years ago. Therefore, the escalating demand for precision medicine is driving the gastrointestinal stromal tumor market's expansion.

Who Are the Top Competitors in Key Gastrointestinal Stromal Tumor Market Segments?
Major companies operating in the gastrointestinal stromal tumor market report are Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck & Co. Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Eli Lilly and Company, Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Jiangsu Hengrui Medicine Co. Ltd., Exelixis Inc., NATCO Pharma Ltd., Blueprint Medicines Corporation, Array BioPharma Inc., Deciphera Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Boston Biomedical Inc., DNAtrix Inc., Advenchen Laboratories LLC, Arog Pharmaceuticals Inc., AB Sciences S.A.

What Gastrointestinal Stromal Tumor Market Trends Are Gaining Traction Across Different Segments?
Leading businesses in the gastrointestinal stromal tumor market are venturing into the development of novel drugs, such as QINLOCK (Ripretinib), in an effort to reach a broader consumer audience and enhance sales and revenue. QINLOCK (Ripretinib) is a prescribed pharmaceutical utilized in the treatment of advanced gastrointestinal stromal tumor (GIST). For example, in January 2024, records from the US Food and Drug Administration (FDA), a federal agency of the United States, show that the CDER novel drug approvals rose from 37 in 2022 to 55 in 2023. It is also worth noting that out of these 55 new drugs, CDER classified 20 (equivalent to 36%) as first-in-class in 2023.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/gastrointestinal-stromal-tumor-global-market-report

Which Regions Are Becoming Hubs for Gastrointestinal Stromal Tumor Market Innovation?
North America was the largest region in the gastrointestinal stromal tumor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal stromal tumor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Gastrointestinal Stromal Tumor Market?
2. What is the CAGR expected in the Gastrointestinal Stromal Tumor Market?
3. What Are the Key Innovations Transforming the Gastrointestinal Stromal Tumor Industry?
4. Which Region Is Leading the Gastrointestinal Stromal Tumor Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.